Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to -$1.9 million.

  • Kyntra Bio's Free Cash Flow rose 7805.63% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.1 million, marking a year-over-year increase of 8646.04%. This contributed to the annual value of -$138.3 million for FY2024, which is 5645.75% up from last year.
  • As of Q3 2025, Kyntra Bio's Free Cash Flow stood at -$1.9 million, which was up 7805.63% from $12.7 million recorded in Q2 2025.
  • Over the past 5 years, Kyntra Bio's Free Cash Flow peaked at $42.7 million during Q3 2021, and registered a low of -$111.6 million during Q2 2023.
  • Its 5-year average for Free Cash Flow is -$35.8 million, with a median of -$34.0 million in 2022.
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 251402.71% in 2021, then tumbled by 91030.26% in 2023.
  • Over the past 5 years, Kyntra Bio's Free Cash Flow (Quarter) stood at -$56.4 million in 2021, then grew by 6.23% to -$52.8 million in 2022, then surged by 64.86% to -$18.6 million in 2023, then plummeted by 64.8% to -$30.6 million in 2024, then soared by 93.94% to -$1.9 million in 2025.
  • Its Free Cash Flow stands at -$1.9 million for Q3 2025, versus $12.7 million for Q2 2025 and $2.7 million for Q1 2025.